Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Suspended 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 3Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Neuroblastoma 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Congenital Abnormalities 1Breast Neoplasms 1

Interventions

Rituximab 205Cyclophosphamide 178Peripheral Blood Stem Cell Transplantation 93Etoposide 91fludarabine phosphate 86Filgrastim 81Melphalan 62Vincristine 60Mycophenolic Acid 58Busulfan 58Whole-Body Irradiation 57Cytarabine 51Radiotherapy 49Doxorubicin 49Cyclosporine 49Tacrolimus 48Granulocyte Colony-Stimulating Factor 48Prednisone 46fludarabine 45Bendamustine Hydrochloride 45Methotrexate 44Carmustine 36Antilymphocyte Serum 34Dexamethasone 32Bortezomib 29Gemcitabine 27ibritumomab tiuxetan 25Methylprednisolone 23sargramostim 22Stem Cell Transplantation 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, Non-Hodgkin × IL32 protein, human × Clear all
NCT01181258 2018-02-06

MT2009-15

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
16 enrolled 8 charts
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡